Pear Therapeutics

Product Pipeline

Product Name or
Candidate #1
Therapeutic Area/Indication Development Stage Content Partner
Psychiatry Label
Discovery2 Proof of Concept3 Pivotal4 Commercial
reSET Logo Substance use disorder
Dartmouth Logo
reSET-O Logo Opioid use disorder
Dartmouth Logo
Somryst Logo Chronic insomnia
University of Virginia Logo
Pear-009 Alcohol use disorder
Pear-004 Schizophrenia
Pear-011 Anxiety (GAD)
Pear-015 Depression (MDD)
Waypoint Logo
Pear-017 Bipolar
Pear-005 Posttraumatic stress disorder
USC Logo
Neurology Label
Pear-010 Acute and chronic pain
Firsthand Technology Logo
Pear-014 Migraine
Cincinnati Children's Logo
Pear-006 Multiple sclerosis
Pear-013 Epilepsy
Other Label
Pear-012 Irritable bowel syndrome
Karolinska Logo
Pear-018 Specialty gastroenterology
Ironwood Logo
Pear-016 Oncology
Apricity Logo
Pear-019 Cardiovascular

Abbreviations: GAD, generalized anxiety disorder; MDD, major depressive disorder.

*Dartmouth transaction is with a researcher employed by Dartmouth. Pear has
no direct contractual relationship with Dartmouth relating to this content.
Karolinska transaction is with individual researchers who are employed by the
Karolinska Institute. Pear has no direct contractual relationship with the
Karolinkska Institute relating to this content.
Services agreement with Ironwood to evaluate a PDT in gastrointestinal diseases.

PLATFORM
ENHANCEMENTS
DIGITAL BIOMARKERS

  1. Candidates (identified as Pear-xxx) are under development at Pear and have not been evaluated for safety or effectiveness by the U.S. Food and Drug Administration. The development process is uncertain and these candidates may not become commercial products in the future. Discovery is the concept stage before clinical development, in which the product candidate, its mechanism(s) of action and target patient population(s) are defined, technical capabilities and prototypes are built, and then the candidate concept is rapidly tested in iterative evaluations.

  2. Discovery is the concept stage before clinical development, in which the product candidate, its mechanism(s) of action and target patient population(s) are defined, technical capabilities and prototypes are built, and then the candidate concept is rapidly tested in iterative evaluations.

  3. Proof of Concept is the early clinical development stage, in which the product candidate is being tested in human clinical trials designed to prove that the candidate concept is worthy of advancement to the Pivotal stage. POC stage activities are related to technical work, study design, planning, other operational clinical trial activities, and statistical analysis.

  4. Pivotal is the registrational phase, in which the product candidate is tested in a randomized controlled trial designed to support market authorization from a regulatory authority such as FDA. Pivotal stage activities are related to technical work, study design, planning, other operational clinical trial activities, and/or statistical analysis that are part of a regulatory submission.